Renaissance Technologies
CALT

Renaissance Technologies’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Renaissance Technologies’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,600
Closed -$294K – 4297
2021
Q3 		$294K Buy
+13,600
New +$373K ﹤0.01% 3092

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Renaissance Technologies's CALT Position: Q4 2021 in Review

Renaissance Technologies sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2021, closing a stake of 13,600 shares — an estimated $294K sold.

Renaissance Technologies first reported a position in CALT in Q3 2021 and held it in 1 quarter. The position peaked at $294K in Q3 2021. 17 funds tracked by Wall St. Rank hold CALT as of Q4 2021.

  • Renaissance Technologies reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • Renaissance Technologies sold 13,600 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2021, an estimated $294K.
  • Renaissance Technologies first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2021 and held it in 1 quarter.
  • Renaissance Technologies's Calliditas Therapeutics AB American Depositary Shares position peaked at $294K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2021.

Based on Renaissance Technologies's 13F filing for Q4 2021, filed 11 Feb 2022.